What diseases are Eltrombopag ethanolamine tablets used to treat?

Eltrombopag is an oral thrombopoietin receptor agonist, mainly used to treat specific hematological diseases, especially those related to thrombocytopenia.

1.Chronic immune (idiopathic) thrombocytopenia (ITP)

Eltrombopag ethanolamine tablets are mainly used to treat adults and children with chronic immune (idiopathic) thrombocytopenia (ITP) who have poor response to traditional treatments such as glucocorticoids and immunoglobulins. ITPIt is an autoimmune disease in which the patient's immune system mistakenly attacks and destroys its own platelets, resulting in a reduced number of platelets and an increased risk of bleeding. Eltrombopag ethanolamine tablets stimulate the proliferation and differentiation of megakaryocytes in the bone marrow and increase the production of platelets, thereby improving the patient's platelet count and bleeding symptoms.

2.Aplastic anemia (AA)

Eltrombopag ethanolamine tablets are also suitable for patients with severe aplastic anemia (AA), especially those who have poor response to immunosuppressive therapy. AA is a bone marrow failure disease in which the patient's bone marrow fails to produce enough blood cells, including red blood cells, white blood cells and platelets. Eltrombopag ethanolamine tablets can help improve platelet counts and bleeding symptoms in AA patients by promoting the production of platelets.

3.Solid tumor-associated thrombocytopenia

Thrombocytopenia due to radiation, chemotherapy, or targeted drug therapy is also a common problem in some patients with solid tumors. Eltrombopag ethanolamine tablets can be used in these patients to help them increase platelet counts and reduce the risk of bleeding caused by thrombocytopenia.

atITPAmong patients, Eltrombopag ethanolamine tablets have shown significant clinical efficacy. According to the results of multiple randomized controlled trials, compared with placebo, eltrombopag ethanolamine tablets can significantly increase patients' platelet counts, reduce the occurrence of bleeding events, and improve patients' quality of life. For example, in a randomized controlled trial of adult patients with ITP, approximately 60% of patients treated with eltrombopag ethanolamine tablets achieved treatment goals for platelet counts (≥ 50×10⁹/L), while only about 11% in the placebo group. In addition, Eltrombopag ethanolamine tablets can also reduce patients' dependence on glucocorticoids and reduce the risk of side effects caused by long-term use of glucocorticoids.

Eltrombopag ethanolamine tablets also showed good clinical efficacy inAA patients. A randomized controlled trial of patients with severe AA showed that more patients treated with eltrombopag ethanolamine tablets achieved transfusion independence and improved platelet counts compared with placebo. In addition, Eltrombopag ethanolamine tablets can also improve patients' neutrophil count and hemoglobin levels, further reducing the risk of infection and anemia.

In patients with solid tumors, Eltrombopag ethanolamine tablets also showed the effect of increasing platelet counts. A randomized controlled trial of patients with advanced malignancies showed that more patients treated with eltrombopag ethanolamine tablets achieved improved platelet counts and reduced the risk of bleeding due to thrombocytopenia. This result helps improve patients' quality of life and may reduce the need to interrupt or delay chemotherapy due to thrombocytopenia.